Article Text

PDF
Epidemiology
Trends in secondary prevention of ischaemic heart disease in the UK 1994–2005: use of individual and combination treatment
  1. S DeWilde1,
  2. I M Carey1,
  3. N Richards2,
  4. P H Whincup1,
  5. D G Cook1
  1. 1
    Division of Community Health Sciences, St George’s, University of London, UK
  2. 2
    Cegedim Strategic Data Ltd, Surrey, UK
  1. Professor D G Cook, Division of Community Health Sciences, St George’s, University of London, Cranmer Terrace, London SW17 0RE, UK; d.cook{at}sgul.ac.uk

Abstract

Background: Statins, antiplatelet drugs, β-blockers and ACE inhibitors may produce marked benefits in secondary prevention of ischaemic heart disease (IHD), especially in combination.

Objective: To examine trends in treatment and factors associated with treatment using a population-based general practice database.

Design: Analysis of routinely collected computerised data from 201 general practices using iSOFT software contributing to the DIN-LINK database.

Setting and patients: Subjects aged ⩾35 years and registered with the practices; on average, 30 000 men and 21 000 women with IHD each year.

Main outcome measure: Percentage of subjects with IHD receiving individual drugs and combined treatment in any given year.

Results: Between 1994 and 2005 use of drugs for secondary prevention increased markedly. By 2005, 80% of men and 70% of women were receiving a statin, 75% and 74% were receiving antiplatelet drugs, 55% and 48% were receiving β-blockers and 57% and 51% were receiving an ACE inhibitor; 55% of men and 46% of women were receiving a statin, antiplatelet drug and either β-blocker or ACE inhibitor, of whom just under half were receiving all four classes of drug. Gender differences were largely explained by more severe disease in men. In 2005, subjects less likely to receive combination therapy were older, had not had a myocardial infarction or revascularisation, and lacked comorbidities such as diabetes or hypertension.

Conclusions: Despite high levels of statin and antiplatelet prescribing, opportunities exist for increasing the benefits of secondary prevention, especially through the wider use of combined treatments. Future targets could usefully include combination therapy.

Statistics from Altmetric.com

Footnotes

  • Competing interests: NR is a director of Cegedim Strategic Data, which markets DIN-LINK data to pharmaceutical companies.

  • Ethics approval: Ethical approval for use of the DIN-LINK database for this project was given by the Wandsworth research ethics committee.

  • Funding: This project was funded by the BUPA Foundation. The Wellcome Trust funded the development of the database. SDeW is part funded by a grant from Cegedim.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles